216 related articles for article (PubMed ID: 33990633)
1. EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma.
Lee JY; Kim JH; Bang H; Cho J; Ko YH; Kim SJ; Kim WS
Sci Rep; 2021 May; 11(1):10342. PubMed ID: 33990633
[TBL] [Abstract][Full Text] [Related]
2. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.
Wang L; Wang Z; Xia ZJ; Lu Y; Huang HQ; Zhang YJ
Tumour Biol; 2015 Sep; 36(10):7717-23. PubMed ID: 25935537
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma.
Yoo C; Yoon DH; Jo JC; Yoon S; Kim S; Lee BJ; Huh J; Lee SW; Suh C
Ann Hematol; 2014 Jun; 93(6):995-1000. PubMed ID: 24441948
[TBL] [Abstract][Full Text] [Related]
4. Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1.
Feng Y; Jing C; Yu X; Cao X; Xu C
Hematol Oncol; 2020 Oct; 38(4):467-477. PubMed ID: 32515093
[TBL] [Abstract][Full Text] [Related]
5. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.
Feng Y; Rao H; Lei Y; Huang Y; Wang F; Zhang Y; Xi S; Wu Q; Shao J
Chin J Cancer; 2017 May; 36(1):43. PubMed ID: 28486951
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous extranodal natural killer/T-cell lymphoma: a comparative clinicohistopathologic and survival outcome analysis of 45 cases according to the primary tumor site.
Lee WJ; Jung JM; Won CH; Chang SE; Choi JH; Chan Moon K; Park CS; Huh J; Lee MW
J Am Acad Dermatol; 2014 Jun; 70(6):1002-9. PubMed ID: 24629518
[TBL] [Abstract][Full Text] [Related]
7. Both c-Myc and Ki-67 expression are predictive markers in patients with extranodal NK/T-cell lymphoma, nasal type: a retrospective study in China.
Huang X; Sun Q; Fu H; Zhou X; Guan X; Wang J
Pathol Res Pract; 2014 Jun; 210(6):351-6. PubMed ID: 24642368
[TBL] [Abstract][Full Text] [Related]
8. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.
Wang L; Wang ZH; Chen XQ; Li YJ; Wang KF; Xia YF; Xia ZJ
Cancer; 2013 Jan; 119(2):348-55. PubMed ID: 22811078
[TBL] [Abstract][Full Text] [Related]
9. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.
Kim SJ; Yoon DH; Jaccard A; Chng WJ; Lim ST; Hong H; Park Y; Chang KM; Maeda Y; Ishida F; Shin DY; Kim JS; Jeong SH; Yang DH; Jo JC; Lee GW; Choi CW; Lee WS; Chen TY; Kim K; Jung SH; Murayama T; Oki Y; Advani R; d'Amore F; Schmitz N; Suh C; Suzuki R; Kwong YL; Lin TY; Kim WS
Lancet Oncol; 2016 Mar; 17(3):389-400. PubMed ID: 26873565
[TBL] [Abstract][Full Text] [Related]
10. Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type.
Hong J; Park S; Baek HL; Jung JH; Kang IG; Sym SJ; Park J; Ahn JY; Cho EK; Kim ST; Shin DB; Lee JH
Int J Clin Exp Pathol; 2012; 5(9):939-47. PubMed ID: 23119111
[TBL] [Abstract][Full Text] [Related]
11. Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type, is associated with disease progression and prognosis.
Liu J; Liang L; Huang S; Nong L; Li D; Zhang B; Li T
Hum Pathol; 2019 Jan; 83():166-176. PubMed ID: 30218753
[TBL] [Abstract][Full Text] [Related]
12. Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.
Michot JM; Mazeron R; Danu A; Lazarovici J; Ghez D; Antosikova A; Willekens C; Chamseddine AN; Minard V; Dartigues P; Bosq J; Carde P; Koscielny S; De Botton S; Ferme C; Girinsky T; Ribrag V
Eur J Cancer; 2015 Nov; 51(16):2386-95. PubMed ID: 26254810
[TBL] [Abstract][Full Text] [Related]
13. Dynamic evaluation of the prognostic value of
Xu P; Guo R; You J; Cheng S; Li J; Zhong H; Sun C; Xu H; Huang H; Li B; Zhao W
Ann Hematol; 2021 Apr; 100(4):1039-1047. PubMed ID: 33634350
[TBL] [Abstract][Full Text] [Related]
14. LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphoma, nasal type (ENKTL).
Mao Y; Zhang DW; Zhu H; Lin H; Xiong L; Cao Q; Liu Y; Li QD; Xu JR; Xu LF; Chen RJ
Diagn Pathol; 2012 Dec; 7():178. PubMed ID: 23237707
[TBL] [Abstract][Full Text] [Related]
15. Prognostic indicators of survival in sinonasal extranodal natural killer/T-cell lymphoma.
Varelas AN; Ganti A; Eggerstedt M; Tajudeen BA
Laryngoscope; 2019 Dec; 129(12):2675-2680. PubMed ID: 30801751
[TBL] [Abstract][Full Text] [Related]
16. "Sandwich" Chemotherapy (CT) with Radiotherapy (RT) improves outcomes in patients with stage IE/IIE extranodal natural killer (NK)/T-cell Lymphomas.
Zhang J; Zhu MY; Wang L; Wang H; Wang WD; Geng QR; Lu Y
Asian Pac J Cancer Prev; 2013; 14(7):4061-6. PubMed ID: 23991953
[TBL] [Abstract][Full Text] [Related]
17. Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type.
Huang Y; Yang J; Liu P; Zhou S; Gui L; He X; Qin Y; Zhang C; Yang S; Xing P; Sun Y; Shi Y
Ann Hematol; 2017 Sep; 96(9):1477-1483. PubMed ID: 28695246
[TBL] [Abstract][Full Text] [Related]
18. High IL-6 expression in the tumor microenvironment is associated with poor prognosis of patients with extranodal natural / killer T-cell lymphoma (ENKTL).
Rong Q; Gao Y; Cai Q; Wang X; Bai B; Ping L; He H; Rao H; Zhang Y; Li Z; Cai Q; Jiang W; Huang H
Expert Rev Anticancer Ther; 2021 Jan; 21(1):121-127. PubMed ID: 33397158
[No Abstract] [Full Text] [Related]
19. Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases.
Su YJ; Wang PN; Chang H; Shih LY; Lin TL; Kuo MC; Chuang WY; Wu JH; Tang TC; Hung YS; Dunn P; Kao HW
Eur J Haematol; 2018 Sep; 101(3):379-388. PubMed ID: 29908084
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Nomogram for Overall Survival in Extranodal Natural Killer/T-Cell Lymphoma Patients.
Li K; Wang R; Huang S; Pan X; Chen H; Zhou L; Wei J; Wu C; Zhu X; Liang S; Qu S
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e537-e543. PubMed ID: 30243570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
